A combination of YM-155, a small molecule survivin inhibitor, and IL-2 potently suppresses renal cell carcinoma in murine model

YM155, a small molecule inhibitor of the antiapoptotic protein survivin, has been developed as a potential anti-cancer drug. We investigated a combination therapy of YM155 and interleukin-2 (IL-2) in a mouse model of renal cell carcinoma (RCC). YM155 caused cell cycle arrest and apoptosis in renal c...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Kai, Huang, Peng, Xu, Naijin, Xu, Peng, Kaku, Haruki, Zheng, Shaobo, Xu, Abai, Matsuura, Eiji, Liu, Chunxiao, Kumon, Hiromi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673255/
https://www.ncbi.nlm.nih.gov/pubmed/26023798
_version_ 1782404701451452416
author Guo, Kai
Huang, Peng
Xu, Naijin
Xu, Peng
Kaku, Haruki
Zheng, Shaobo
Xu, Abai
Matsuura, Eiji
Liu, Chunxiao
Kumon, Hiromi
author_facet Guo, Kai
Huang, Peng
Xu, Naijin
Xu, Peng
Kaku, Haruki
Zheng, Shaobo
Xu, Abai
Matsuura, Eiji
Liu, Chunxiao
Kumon, Hiromi
author_sort Guo, Kai
collection PubMed
description YM155, a small molecule inhibitor of the antiapoptotic protein survivin, has been developed as a potential anti-cancer drug. We investigated a combination therapy of YM155 and interleukin-2 (IL-2) in a mouse model of renal cell carcinoma (RCC). YM155 caused cell cycle arrest and apoptosis in renal cancer (RENCA) cells. Next, luciferase-expressing RENCA cells were implanted in the left kidney and the lung of BALB/c mice to develop RCC metastatic model. In this orthotopic renal and metastatic lung tumors models, YM155 and IL-2 additively decreased tumor weight, lung metastasis, and luciferin-stained tumor images. Also, the combination significantly suppressed regulatory T cells and myeloid-derived suppressor cells compared with single agent treatment. We suggest that a combination of YM155 and IL-2 can be tested as a potential therapeutic modality in patients with RCC.
format Online
Article
Text
id pubmed-4673255
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-46732552015-12-22 A combination of YM-155, a small molecule survivin inhibitor, and IL-2 potently suppresses renal cell carcinoma in murine model Guo, Kai Huang, Peng Xu, Naijin Xu, Peng Kaku, Haruki Zheng, Shaobo Xu, Abai Matsuura, Eiji Liu, Chunxiao Kumon, Hiromi Oncotarget Research Paper YM155, a small molecule inhibitor of the antiapoptotic protein survivin, has been developed as a potential anti-cancer drug. We investigated a combination therapy of YM155 and interleukin-2 (IL-2) in a mouse model of renal cell carcinoma (RCC). YM155 caused cell cycle arrest and apoptosis in renal cancer (RENCA) cells. Next, luciferase-expressing RENCA cells were implanted in the left kidney and the lung of BALB/c mice to develop RCC metastatic model. In this orthotopic renal and metastatic lung tumors models, YM155 and IL-2 additively decreased tumor weight, lung metastasis, and luciferin-stained tumor images. Also, the combination significantly suppressed regulatory T cells and myeloid-derived suppressor cells compared with single agent treatment. We suggest that a combination of YM155 and IL-2 can be tested as a potential therapeutic modality in patients with RCC. Impact Journals LLC 2015-05-12 /pmc/articles/PMC4673255/ /pubmed/26023798 Text en Copyright: © 2015 Guo et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Guo, Kai
Huang, Peng
Xu, Naijin
Xu, Peng
Kaku, Haruki
Zheng, Shaobo
Xu, Abai
Matsuura, Eiji
Liu, Chunxiao
Kumon, Hiromi
A combination of YM-155, a small molecule survivin inhibitor, and IL-2 potently suppresses renal cell carcinoma in murine model
title A combination of YM-155, a small molecule survivin inhibitor, and IL-2 potently suppresses renal cell carcinoma in murine model
title_full A combination of YM-155, a small molecule survivin inhibitor, and IL-2 potently suppresses renal cell carcinoma in murine model
title_fullStr A combination of YM-155, a small molecule survivin inhibitor, and IL-2 potently suppresses renal cell carcinoma in murine model
title_full_unstemmed A combination of YM-155, a small molecule survivin inhibitor, and IL-2 potently suppresses renal cell carcinoma in murine model
title_short A combination of YM-155, a small molecule survivin inhibitor, and IL-2 potently suppresses renal cell carcinoma in murine model
title_sort combination of ym-155, a small molecule survivin inhibitor, and il-2 potently suppresses renal cell carcinoma in murine model
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673255/
https://www.ncbi.nlm.nih.gov/pubmed/26023798
work_keys_str_mv AT guokai acombinationofym155asmallmoleculesurvivininhibitorandil2potentlysuppressesrenalcellcarcinomainmurinemodel
AT huangpeng acombinationofym155asmallmoleculesurvivininhibitorandil2potentlysuppressesrenalcellcarcinomainmurinemodel
AT xunaijin acombinationofym155asmallmoleculesurvivininhibitorandil2potentlysuppressesrenalcellcarcinomainmurinemodel
AT xupeng acombinationofym155asmallmoleculesurvivininhibitorandil2potentlysuppressesrenalcellcarcinomainmurinemodel
AT kakuharuki acombinationofym155asmallmoleculesurvivininhibitorandil2potentlysuppressesrenalcellcarcinomainmurinemodel
AT zhengshaobo acombinationofym155asmallmoleculesurvivininhibitorandil2potentlysuppressesrenalcellcarcinomainmurinemodel
AT xuabai acombinationofym155asmallmoleculesurvivininhibitorandil2potentlysuppressesrenalcellcarcinomainmurinemodel
AT matsuuraeiji acombinationofym155asmallmoleculesurvivininhibitorandil2potentlysuppressesrenalcellcarcinomainmurinemodel
AT liuchunxiao acombinationofym155asmallmoleculesurvivininhibitorandil2potentlysuppressesrenalcellcarcinomainmurinemodel
AT kumonhiromi acombinationofym155asmallmoleculesurvivininhibitorandil2potentlysuppressesrenalcellcarcinomainmurinemodel
AT guokai combinationofym155asmallmoleculesurvivininhibitorandil2potentlysuppressesrenalcellcarcinomainmurinemodel
AT huangpeng combinationofym155asmallmoleculesurvivininhibitorandil2potentlysuppressesrenalcellcarcinomainmurinemodel
AT xunaijin combinationofym155asmallmoleculesurvivininhibitorandil2potentlysuppressesrenalcellcarcinomainmurinemodel
AT xupeng combinationofym155asmallmoleculesurvivininhibitorandil2potentlysuppressesrenalcellcarcinomainmurinemodel
AT kakuharuki combinationofym155asmallmoleculesurvivininhibitorandil2potentlysuppressesrenalcellcarcinomainmurinemodel
AT zhengshaobo combinationofym155asmallmoleculesurvivininhibitorandil2potentlysuppressesrenalcellcarcinomainmurinemodel
AT xuabai combinationofym155asmallmoleculesurvivininhibitorandil2potentlysuppressesrenalcellcarcinomainmurinemodel
AT matsuuraeiji combinationofym155asmallmoleculesurvivininhibitorandil2potentlysuppressesrenalcellcarcinomainmurinemodel
AT liuchunxiao combinationofym155asmallmoleculesurvivininhibitorandil2potentlysuppressesrenalcellcarcinomainmurinemodel
AT kumonhiromi combinationofym155asmallmoleculesurvivininhibitorandil2potentlysuppressesrenalcellcarcinomainmurinemodel

Ejemplares similares